Tranexamic Acid Complete Guide To Uses, Dosage & Side Effects
Comprehensive guide to tranexamic acid: medical uses, dermatological applications, mechanisms, dosing, and safety in treating bleeding and pigmentation disorders.
Tranexamic acid (TXA) is a synthetic antifibrinolytic agent derived from the amino acid lysine. It competitively inhibits plasminogen activation, stabilising fibrin clots to reduce or prevent excessive bleeding. Initially developed for haemostatic purposes, TXA has gained prominence in dermatology for treating pigmentary disorders such as melasma due to its ability to modulate melanin synthesis pathways.Who is it for? TXA is suitable for patients with hyperfibrinolytic bleeding disorders, heavy menstrual bleeding, and hyperpigmentary skin conditions resistant to standard therapies.
What is tranexamic acid?
Tranexamic acid is a small-molecule synthetic lysine analogue patented in 1957 and first approved by the US FDA in 1986 for antifibrinolytic use. It functions by binding to plasminogen at multiple sites, including a high-affinity lysine-binding site, preventing its activation to plasmin—the primary enzyme responsible for fibrinolysis (clot breakdown). This clot stabilisation mechanism is approximately 10 times more potent than epsilon-aminocaproic acid, its predecessor.
In dermatology, TXA’s off-label application targets hyperpigmentation by inhibiting UV-induced plasminogen activation in keratinocytes, which reduces free arachidonic acid and subsequent melanocyte stimulation via the plasmin/plasminogen pathway. This interrupts melanin production without the cytotoxicity associated with hydroquinone.
- Chemical structure: Trans-4-(aminomethyl)cyclohexanecarboxylic acid.
- Forms: Oral tablets (500–650 mg), intravenous (IV) solution (100 mg/mL), topical solutions (2–5%).
- Bioavailability: ~30–50% oral; peak plasma levels in 3 hours.
What is tranexamic acid used for?
TXA’s FDA-approved indications focus on bleeding control, but extensive off-label use spans surgical, obstetric, traumatic, and dermatological contexts.
Bleeding disorders
Heavy menstrual bleeding (menorrhagia): Oral TXA (1.3 g three times daily for up to 5 days) reduces blood loss by 26–60% in women with idiopathic menorrhagia, improving quality of life comparable to intranasal desmopressin or danazol.
Hemophilia: Short-term IV or oral use (2–8 days) post-tooth extraction prevents bleeding when combined with factor replacement. Cochrane reviews confirm reduced postoperative haemorrhage.
Surgical and trauma applications
In trauma, IV TXA (1 g bolus over 10 min, followed by 1 g infusion over 8 hours) within 3 hours of injury reduces mortality from haemorrhage by 1.5% in the CRASH-2 trial (n=20,211). Benefits diminish if given >3 hours post-injury.
Off-label surgical uses include:
- Cardiac surgery: Reduces transfusion needs by 30–50%.
- Orthopaedic (e.g., spinal fusion, hip/knee arthroplasty): Lowers total blood loss by 200–500 mL.
- Postpartum haemorrhage: WOMAN trial (n=20,060) showed 19% relative mortality reduction when given early.
- TURP prostatectomy: Decreases rebleeding risk.
Dermatological uses
TXA is increasingly used for melasma, post-inflammatory hyperpigmentation (PIH), and erythema. Oral doses (250–1500 mg/day) for 8–12 weeks yield 49–66% improvement in Melasma Area Severity Index (MASI) scores, often superior to topical hydroquinone with fewer side effects.
| Treatment | MASI Reduction (%) | Side Effects |
|---|---|---|
| Oral TXA 250 mg BID | 49–66 | Gastrointestinal upset (5–10%) |
| Topical TXA 3–5% | 22–49 | Mild irritation (<5%) |
| Hydroquinone 4% | 40–60 | Irritation, ochronosis (rare) |
Topical TXA strengthens the skin barrier in rosacea, reducing symptoms via improved stratum corneum integrity. It also fades acne-related PIH and UV-induced spots.
How does tranexamic acid work?
The core mechanism is reversible inhibition of plasminogen-to-plasmin conversion by occupying lysine-binding sites on plasminogen, blocking its interaction with fibrin. This prevents fibrinolysis, stabilising haemostatic plugs.
In skin:
- Inhibits keratinocyte plasminogen activator, reducing arachidonic acid release.
- Downregulates VEGF, endothelin-1, and stem cell factor—key melanogenic stimuli.
- Anti-inflammatory effects via reduced plasmin-mediated complement activation.
Off-target: GABA_A antagonism at high doses may cause seizures, particularly IV during surgery.
Routes of administration
- Oral: 1–1.3 g TID for menorrhagia; 250–500 mg BID for melasma (max 1500 mg/day).
- IV: 10 mg/kg (max 1 g) bolus + infusion for acute bleeding.
- Topical: 2–5% solution/serum BID; liposomal formulations enhance penetration.
Dosage and administration
Menorrhagia: 1300 mg (two 650 mg tablets) PO TID x5 days during menses.
Melasma: Oral 250 mg BID x8–12 weeks; topical 3% BID. Combine with sunscreen (SPF 50+).
Trauma: 1 g IV x1, then 1 g over 8h within 3h injury.
Adjust for renal impairment (CrCl <30 mL/min: halve dose). Discontinue if no response in 6 months for pigmentary uses.
Side effects and risks
TXA is well-tolerated; most adverse effects are dose-related and mild.
- Common (>5%): Nausea, vomiting, diarrhoea, hypotension (IV).
- Serious (rare): Thrombosis (0.4–1.2%; VTE risk not elevated in meta-analyses), seizures (high-dose IV), colour vision changes, anaphylaxis.
- Dermatological: Minimal—transient irritation topically.
Contraindications: Active thromboembolism, subarachnoid haemorrhage, acquired defective colour vision, severe renal failure.
| Event | Oral (%) | IV (%) |
|---|---|---|
| Gastrointestinal | 10–20 | 5–10 |
| Thromboembolism | <1 | 0.5–1 |
| Seizures | Rare | 0.1–1 (high dose) |
Drug interactions
- Prothrombotic agents: Factor IX, estrogens—increased thrombosis risk.
- Oral contraceptives: Monitor for bleeding/spotting.
- Tamoxifen: Contraindicated.
Preparation and storage
Store tablets at room temperature (15–30°C); IV solution protected from light. Reconstitute IV per manufacturer guidelines.
Alternative agents
- Bleeding: Epsilon-aminocaproic acid, desmopressin.
- Melasma: Hydroquinone, azelaic acid, cysteamine, oral polypodium leucotomos.
Patient information
Use sunscreen daily; report vision changes, chest pain, or swelling immediately. Not for long-term use without monitoring.
Investigations
Baseline: Renal function, LFTs, coagulation profile. Monitor for melasma: MASI scoring, Wood lamp. Thrombophilia screen if high-risk.
Frequently asked questions
How long does oral tranexamic acid take to work for melasma?
Visible lightening in 4–8 weeks; optimal results at 12 weeks. Maintenance topical therapy recommended.
Is tranexamic acid safe during pregnancy?
Category B; avoid unless benefits outweigh risks (e.g., postpartum haemorrhage). Limited data.
Can topical TXA be used with retinol?
Yes, but alternate days to minimise irritation. Start low concentration.
Does TXA cause hypopigmentation?
Rare; reversible upon discontinuation. Safer profile than bleaching agents.
What if I miss a dose?
Take as soon as remembered; skip if near next dose. Do not double.
References
- Tranexamic acid: Uses, Interactions, Mechanism of Action — DrugBank Online. 2023-10-15. https://go.drugbank.com/drugs/DB00302
- Tranexamic Acid — StatPearls, NCBI Bookshelf. 2024-07-24. https://www.ncbi.nlm.nih.gov/books/NBK532909/
- Tranexamic Acid for Skin: Benefits, Safety, How to Use — Healthline. 2023-05-12. https://www.healthline.com/health/beauty-skin-care/tranexamic-acid-for-skin
- Tranexamic Acid — MedlinePlus, U.S. National Library of Medicine. 2024-01-15. https://medlineplus.gov/druginfo/meds/a612021.html
- Tranexamic acid (oral route) — Mayo Clinic. 2023-11-01. https://www.mayoclinic.org/drugs-supplements/tranexamic-acid-oral-route/description/drg-20073517
Similar Articles
Read full bio of medha deb
